QNCX - Quince Therapeutics, Inc.
1.27
-0.100 -7.874%
Share volume: 1,707,213
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.37
-0.10
-0.07%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-13-2024 | 08-13-2024 | 11-13-2024 | 03-24-2025 | 05-13-2025 | 08-11-2025 | 11-12-2025 | |
| Assets | ||||||||
| Total Assets | 159.292 M | 134.829 M | 126.519 M | 114.478 M | 107.089 M | 117.210 M | 109.899 M | |
| Current Assets | 70.439 M | 63.438 M | 51.718 M | 44.036 M | 33.829 M | 37.345 M | 29.202 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 46.010 M | 51.555 M | 45.172 M | 34.572 M | 23.828 M | 17.882 M | 19.836 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 21.813 M | 7.890 M | 2.675 M | 6.212 M | 7.771 M | 16.826 M | 6.452 M | |
| Total Non-current Assets | 78.000 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 234.000 K | 246.000 K | 208.000 K | 315.000 K | 448.000 K | 573.000 K | 616.000 K | |
| Other Assets | 88.619 M | 71.145 M | 74.593 M | 70.127 M | 72.812 M | 79.292 M | 80.081 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 159.292 M | 134.829 M | 126.519 M | 114.478 M | 107.089 M | 117.210 M | 109.899 M | |
| Total liabilities | 85.115 M | 87.861 M | 81.587 M | 84.332 M | 88.508 M | 105.474 M | 108.840 M | |
| Total current liabilities | 9.838 M | 10.321 M | 5.425 M | 7.278 M | 8.356 M | 7.467 M | 26.044 M | |
| Accounts Payable | 2.070 M | 2.405 M | 1.622 M | 2.903 M | 3.008 M | 1.759 M | 3.403 M | |
| Other liabilities | 56.582 M | 58.533 M | 55.881 M | 57.770 M | 59.714 M | 75.423 M | 77.203 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 13.518 M | 13.834 M | 14.899 M | 14.321 M | 15.266 M | 16.989 M | 0.000 | |
| Other liabilities | 56.582 M | 58.533 M | 55.881 M | 57.770 M | 59.714 M | 75.423 M | 77.203 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 74.177 M | 46.968 M | 44.932 M | 30.146 M | 18.581 M | 11.736 M | 1.059 M | |
| Common stock | 403.145 M | 404.403 M | 405.527 M | 406.653 M | 408.126 M | 413.131 M | 415.759 M | |
| Retained earnings | -330.793 M | -358.522 M | -364.014 M | -376.472 M | -391.502 M | -407.551 M | -420.993 M |